Prelude Therapeutics (PRLD) Operating Leases (2021 - 2026)

Prelude Therapeutics has reported Operating Leases for 6 years, with the latest figure at $15.0 million in Q1 2026.

• Quarterly Operating Leases fell 2.01% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (down 2.01% YoY) and the FY2025 annual result came in at $15.0 million, down 1.83% from the prior year.
• Operating Leases fell to $15.0 million in Q1 2026 per PRLD's latest filing, from $15.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $16.9 million in Q4 2023 and troughed at $390000.0 in Q1 2022.
• A 5-year average of $14.0 million and a median of $15.3 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2025: Operating Leases slumped 53.57% in 2022, then declined 1.2% in 2025.
• Over 5 years, Operating Leases stood at $390000.0 in 2022, then soared by 4230.26% to $16.9 million in 2023, then declined by 9.26% to $15.3 million in 2024, then retreated by 1.83% to $15.0 million in 2025, then decreased by 0.56% to $15.0 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $15.0 million, $15.0 million, and $15.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.